Galderma released clinical data demonstrating high effectiveness, satisfaction, and safety for Restylane Volyme in Chinese patients with temple hollowing—a targeted indication that opens a new revenue stream in the world's second-largest aesthetics market. Temple augmentation is a distinct aesthetic priority in Asia, where volume loss in that zone drives visible aging.
Injectables
Galderma's Restylane Volyme Clears China Temple Study—Regional Expansion Accelerates
Galderma announced positive clinical data for Restylane Volyme in Chinese patients with temple hollowing, signaling aggressive geographic expansion.
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Restylane Volyme showed high effectiveness and satisfaction in Chinese patients with temple hollowing.
This study result positions Restylane Volyme as a regional workhorse filler. Galderma is building indication-specific clinical evidence to justify premium pricing and market share gains in China, where competition from domestic and Korean brands is intense. For U.S. practices, the data reinforces Volyme's rheology advantage in structural support—the same mechanism that works for temples works for cheeks, jawline, and chin. Galderma's launch investment is paying off as clinical evidence accumulates.
Source: original report ↗
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.